Nanotechnology in the Treatment of Glioblastoma Multiforme: Enhancing Radiotherapy and Chemotherapy with Nanoparticles
DOI:
https://doi.org/10.12775/JEHS.2025.80.60160Keywords
Glioblastoma multiforme, nanoparticles, drug delivery, blood-brain barrier, targeted therapy, nanomedicine, nanotechnologyAbstract
Introduction:
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, associated with poor prognosis despite standard treatment modalities including surgery, radiotherapy, and chemotherapy. The limited efficacy of these therapies is due, in part, to the difficulty of complete tumor resection, the blood-brain barrier (BBB) hindering drug penetration, and the tumor’s resistance mechanisms to chemotherapy and radiotherapy. Nanoparticles (NPs) offer promising solutions for targeted drug delivery, potentially improving therapeutic outcomes. This review summarizes recent advances in nanoparticle-based therapies for GBM.
Methods:
A literature review was conducted by analyzing 38 scientific articles using PubMed and Google Scholar databases. Studies published within the last five years focusing on the application of nanoparticles in GBM treatment were included. Various types of nanoparticles, their mechanisms of action, and the potential benefits and limitations of their clinical use were discussed.
Results:
The literature indicates that nanoparticles enhance drug permeability across the BBB, improve tumor penetration, and increase treatment efficacy. Their use in GBM therapy enables more precise drug delivery, reduces systemic toxicity, and minimizes damage to healthy tissues. Furthermore, nanoparticles play a significant role in combination therapies, potentially leading to a synergistic therapeutic effect.
Conclusions:
Nanoparticles represent a novel and promising strategy for the treatment of GBM, offering targeted drug delivery and improved therapeutic outcomes. However, further research is needed to optimize nanoparticle formulations and to evaluate their long-term safety and efficacy in clinical settings.
References
1. McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021;374:n1560. doi: 10.1136/bmj.n1560. PMID: 34261630.
2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076.
3. Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023. PMID: 36809318.
4. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020 Jul;70(4):299-312. doi: 10.3322/caac.21613. PMID: 32478924.
5. Chelliah SS, Paul EAL, Kamarudin MNA, Parhar I. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. Molecules. 2021 Feb 22;26(4):1169. doi: 10.3390/molecules26041169. PMID: 33671796.
6. Verdugo E, Puerto I, Medina MÁ. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond). 2022 Nov;42(11):1083-1111. doi: 10.1002/cac2.12361. Epub 2022 Sep 21. PMID: 36129048.
7. Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021 Dec 5;16(1):173. doi: 10.1186/s11671-021-03628-6. PMID: 34866166; PMCID: PMC8645667.
8. Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023 Nov 3;8(1):418. doi: 10.1038/s41392-023-01642-x. PMID: 37919282; PMCID: PMC10622502.
9. Mundekkad D, Cho WC. Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci. 2022 Feb 1;23(3):1685. doi: 10.3390/ijms23031685. PMID: 35163607; PMCID: PMC8835852.
10. Sengar A. The Role of Nanotechnology in Revolutionizing Cancer Treatment. Preprints.org [Preprint]; 2025 Mar 11 doi:10.20944/preprints202503.0713.v1
11. Aghebati-Maleki A, Dolati S, Ahmadi M, Baghbanzhadeh A, Asadi M, Fotouhi A, et al. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020 Mar;235(3):1962-1972. doi: 10.1002/jcp.29126. PMID: 31441032.
12. Hersh AM, Alomari S, Tyler BM. Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int J Mol Sci. 2022 Apr 9;23(8):4153. doi: 10.3390/ijms23084153. PMID: 35456971; PMCID: PMC9032478.
13. Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D, et al. Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies. Mater Today (Kidlington). 2020 Jul-Aug;37:112-125. doi: 10.1016/j.mattod.2020.02.001. PMID: 33093794; PMCID: PMC7575138.
14. Ferraris C, Cavalli R, Panciani PP, Battaglia L. Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours. Int J Nanomedicine. 2020 Apr 30;15:2999-3022. doi: 10.2147/IJN.S231479. PMID: 32431498; PMCID: PMC7201023.
15. Brown TD, Habibi N, Wu D, Lahann J, Mitragotri S. Effect of Nanoparticle Composition, Size, Shape, and Stiffness on Penetration Across the Blood-Brain Barrier. ACS Biomater Sci Eng. 2020 Sep 14;6(9):4916-4928. doi: 10.1021/acsbiomaterials.0c00743. Epub 2020 Aug 31. PMID: 33455287.
16. Gan Y, Yu Y, Xu H, Piao H. Liposomal Nanomaterials: A Rising Star in Glioma Treatment. Int J Nanomedicine. 2024 Jul 5;19:6757-6776. doi: 10.2147/IJN.S470478. PMID: 38983132; PMCID: PMC11232959.
17. Piwowarczyk L, Mlynarczyk DT, Krajka-Kuźniak V, Majchrzak-Celińska A, Budzianowska A, Tomczak S, i in. Natural Compounds in Liposomal Nanoformulations of Potential Clinical Application in Glioblastoma. Cancers (Basel). 2022;14(24):6222. doi: 10.3390/cancers14246222. PMID: 36551708.
18. Kondos N, Sneed K, Pathak Y. Recent Trends in Nano Drug Delivery Systems to Treat Cancers: With Special Focus on Liposomal Drug Delivery Systems. SciBase Oncol. 2024;2(1):1009.
19. Caraway CA, Gaitsch H, Wicks EE, Kalluri A, Kunadi N, Tyler BM. Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches. Polymers (Basel). 2022;14(14):2963. doi: 10.3390/polym14142963. PMID: 35890738; PMCID: PMC9322801.
20. Rabha B, Bharadwaj KK, Pati S, Choudhury BK, Sarkar T, Kari ZA, et al. Development of Polymer-Based Nanoformulations for Glioblastoma Brain Cancer Therapy and Diagnosis: An Update. Polymers (Basel). 2021;13(23):4114. doi: 10.3390/polym13234114. PMID: 34883617; PMCID: PMC8659151.
21. Lansangan C, Khoobchandani M, Jain R, Rudensky S, Perry CC, Patil R. Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives. Materials (Basel). 2024;17(5):1153. doi: 10.3390/ma17051153. PMID: 38473623; PMCID: PMC10934385.
22. Qureshi S, Anjum S, Hussain M, Sheikh A, Gupta G, Almoyad MAA, et al. A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy. Int J Pharm. 2024 Jul 20;660:124301. doi: 10.1016/j.ijpharm.2024.124301. Epub 2024 Jun 6. PMID: 38851411.
23. Pulvirenti L, Monforte F, Lo Presti F, Li Volti G, Carota G, Sinatra F, et al. Synthesis of MIL-Modified Fe₃O₄ Magnetic Nanoparticles for Enhancing Uptake and Efficiency of Temozolomide in Glioblastoma Treatment. Int J Mol Sci. 2022 Mar 6;23(5):2874. doi: 10.3390/ijms23052874. PMID: 35270016; PMCID: PMC8911361.
24. Roque D, Cruz N, Ferreira HA, Reis CP, Matela N, Herculano-Carvalho M, et al. Nanoparticle-Based Treatment in Glioblastoma. J Pers Med. 2023 Aug 29;13(9):1328. doi: 10.3390/jpm13091328. PMID: 37763096; PMCID: PMC10532799.
25. Liu J, Yang F, Hu J, Zhang X. Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives. CNS Neurosci Ther. 2024 May;30(5):e14715. doi: 10.1111/cns.14715. PMID: 38708806; PMCID: PMC11071172.
26. Ruiz-Garcia H, Ramirez-Loera C, Malouff TD, Seneviratne DS, Palmer JD, Trifiletti DM. Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma. Int J Mol Sci. 2021 Sep 7;22(18):9673. doi: 10.3390/ijms22189673. PMID: 34575840; PMCID: PMC8465220.
27. Wen X, Shao Z, Chen X, Liu H, Qiu H, Ding X, et al. A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma. Radiat Oncol. 2024 Sep 12;19(1):119. doi: 10.1186/s13014-024-02511-9. PMID: 39267113; PMCID: PMC11395210.
28. Xie Y, Han Y, Zhang X, Ma H, Li L, Yu R, et al. Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma. Front Oncol. 2021 Mar 22;11:633827. doi: 10.3389/fonc.2021.633827. PMID: 33869019; PMCID: PMC8044949
29. Shen H, Huang H, Jiang Z. Nanoparticle-based radiosensitization strategies for improving radiation therapy. Front Pharmacol. 2023 Feb 16;14:1145551. doi: 10.3389/fphar.2023.1145551. PMID: 36873996; PMCID: PMC9977822.
30. Durand M, Chateau A, Jubréaux J, Devy J, Paquot H, Laurent G, et al. Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma. Int J Nanomedicine. 2023 Jan 13;18:243-261. doi: 10.2147/IJN.S375918. PMID: 36660336; PMCID: PMC9844821.
31. Guerra DB, Oliveira EMN, Sonntag AR, Sbaraine P, Fay AP, Morrone FB, et al. Porównanie radiosensybilizacji indukowanej przez nanocząstki złota i tlenku żelaza w ludzkich komórkach glejaka poddanych napromienianiu fotonami 6 MV. Sci Rep. 2022 Jun 10;12(1):9602. doi: 10.1038/s41598-022-13368-x. PMID: 35688846; PMCID: PMC9187689.
32. Song B, Wang X, Qin L, Hussain S, Liang W. Brain gliomas: Diagnostic and therapeutic issues and the prospects of drug-targeted nano-delivery technology. Pharmacol Res. 2024 Aug;206:107308. doi: 10.1016/j.phrs.2024.107308. PMID: 39019336.
33. Wu H, Wei M, Xu Y, Li Y, Zhai X, Su P, et al. PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment. Int J Nanomedicine. 2022;17:3751-3775. doi: 10.2147/IJN.S378217. PMID: 36065287; PMCID: PMC9440714.
34. Luiz MT, Di Filippo LD, Tofani LB, de Araújo JTC, Dutra JAP, Marchetti JM, et al. Highlights in targeted nanoparticles as a delivery strategy for glioma treatment. Int J Pharm. 2021;604:120758. doi: 10.1016/j.ijpharm.2021.120758. PMID: 34090991.
35. Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, et al. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update. Cancers (Basel). 2021;13(2):195. doi: 10.3390/cancers13020195. PMID: 33430494; PMCID: PMC7827410.
36. Bastiancich C, Da Silva A, Estève MA. Photothermal Therapy for the Treatment of Glioblastoma: Potential and Preclinical Challenges. Front Oncol. 2021;10:610356. doi: 10.3389/fonc.2020.610356. PMID: 33520720; PMCID: PMC7845694
37. Luo D, Wang X, Burda C, Basilion JP. Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis. Cancers (Basel). 2021;13(8):1825. doi: 10.3390/cancers13081825. PMID: 33920453; PMCID: PMC8069007.
38. Hasan I, Roy S, Ehexige E, Wu R, Chen Y, Gao Z, et al. A state-of-the-art liposome technology for glioblastoma treatment. Nanoscale. 2023;15(45):18108-18138. doi: 10.1039/d3nr04241c. PMID: 37937394.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Emilia Gabriela Chrzanowska, Jakub Paweł Kuźniar, Julia Szlążek, Adam Jan Ząbek, Michalina Zagalska, Marta Turek, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska, Michał Kuźniar

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 49
Number of citations: 0